Revolution Medicines Pancreatic Drug Doubles Survival in Landmark Phase 3 Trial
Daraxonrasib posts 13.2 months median OS vs 6.7 for chemo; RVMD hits new highs ahead of ASCO plenary
Photo by Kelly Sikkema on Unsplash
Revolution Medicines' daraxonrasib doubled median survival in metastatic pancreatic cancer versus chemotherapy, setting up a potential first approval for…
The Numbers Speak for Themselves
Revolution Medicines dropped a bombshell at ASCO 2026 that the oncology world has been waiting decades to hear: a real, durable survival benefit in metastatic pancreatic cancer. Daraxonrasib, the company's oral RAS inhibitor, delivered median overall survival of 13.2 months versus 6.7 months for standard chemotherapy in the Phase 3 RASolute 302 trial. That's a hazard ratio of 0.40, which translates to a 60% reduction in the risk of death. The p-value came in below 0.0001.
For context, metastatic pancreatic ductal adenocarcinoma carries a five year survival rate of roughly 3%. Fewer than 20% of patients with metastatic disease survive past one year. The disease has resisted every major therapeutic advance of the past generation. Doubling survival from six to thirteen months doesn't make this cancer easy to treat, but it changes the conversation entirely.
Why This Drug Is Different
Daraxonrasib is part of a new class of drugs called RAS(ON) inhibitors. Pancreatic cancer is the most RAS-addicted of all major cancers: more than 90% of patients harbor RAS mutations, the genetic drivers that have historically been considered undruggable. Revolution's approach uses a small molecule that binds directly to the active, GTP-bound form of RAS, blocking its downstream signaling across G12, G13, and Q61 mutations.
The drug is taken once daily as a pill, not infused intravenously like standard chemotherapy regimens. That difference matters for patients who are already dealing with one of the most debilitating cancers. The trial enrolled roughly 501 patients who had already failed at least one prior line of treatment. Standard of care in this population is essentially palliative, which makes the survival delta even more striking.
The Stock Has Ripped, But the Options Setup Is Instructive
RVMD traded around $34 at its 52 week low and hit fresh highs near $158 this week ahead of the ASCO plenary. The stock has more than quadrupled from its lows, pricing in a lot of the good news before the detailed data dropped. Analysts have been raising targets: Guggenheim lifted to $205 from $175, BofA moved to $185, and the average 12 month target sits around $181.
The company now carries a market cap north of $33 billion. That's big for a clinical stage biotech with no revenue, but the prize is large. Pancreatic cancer kills roughly 50,000 Americans per year and has essentially no effective second line therapy. If daraxonrasib gets approved and captures the market, the revenue potential is substantial. Revolution ended Q1 2026 with $4.0 billion in cash after raising $2.1 billion in concurrent financings, so there's runway to execute on the commercial buildout.
FDA Fast Track and Regulatory Timeline
The FDA granted daraxonrasib breakthrough therapy designation in June 2025 for previously treated metastatic pancreatic cancer with KRAS G12 mutations. Revolution has already received a safe to proceed letter for an expanded access treatment protocol, which means some patients can get the drug before formal approval. The company plans to submit these Phase 3 data to global regulators, including the FDA, as part of a New Drug Application under a Commissioner's National Priority Voucher.
The regulatory path looks as clean as it gets for oncology. A statistically significant survival benefit in a disease with no approved targeted therapies, breakthrough designation already in hand, and a data readout at ASCO's plenary session. The FDA has shown willingness to move quickly on drugs that address unmet need in cancer, and pancreatic cancer sits at the top of that list.
Competitive Landscape and Pipeline Implications
Revolution isn't the only company going after RAS. BridgeBio, Frontier Medicines, and Eli Lilly are all advancing RAS inhibitors in solid tumors. Amgen's Lumakras and Bristol Myers Squibb's Krazati are approved for lung cancer but haven't cracked pancreatic. The RASolute 302 data give Revolution the first mover advantage in the most difficult to treat RAS driven cancer.
Revolution's pipeline extends beyond daraxonrasib. The company is running trials evaluating daraxonrasib in combination with chemotherapy in the first line setting, which could expand the addressable market significantly. Elironrasib, zoldonrasib, and RMC-5127 target different RAS mutations and are moving through clinical development. If the platform works across multiple RAS variants and tumor types, the company becomes much more than a single product story.
What to Watch Next
The full RASolute 302 dataset will be presented at the ASCO plenary session today. Watch for durability of response, quality of life endpoints, and subgroup analyses by mutation type. The FDA submission timeline will be the next major catalyst, with approval likely in 2027 if the review goes smoothly.
Options flow in RVMD has been active, with call buying concentrated in the July and October expirations. The implied volatility remains elevated given the binary nature of regulatory decisions, but the Phase 3 data remove a lot of clinical risk from the story. The stock has to hold the $145 to $150 zone to keep the bullish structure intact. A break below there would signal that the market needs more than survival data to justify the current valuation.
For informational purposes only. Not investment advice. Published Sunday, May 31, 2026.